Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.
Salipro Biotech AB, a Swedish biotech company specialising in the stabilisation of challenging drug targets, today announced a research and license agreement with Boehringer Ingelheim to accelerate ...
Two years after first announcing the partnership, Boehringer Ingelheim and software firm Veeva Systems have launched ...